Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said it vaccinated the first subject in TIDES (Tetravalent Immunization against Dengue Efficacy Study), a phase III double-blind, randomized and placebo-controlled trial of its live-attenuated tetravalent dengue vaccine candidate, TAK-003. The study will enroll about 20,000 healthy children between the ages of 4 and 16 living in dengue-endemic countries in Latin America and Asia.